Peptides for Men Over 40: A Clinician-Guided Framework for Hormonal and Metabolic Restoration

Peptides for men over 40 hormonal health is one of the fastest-growing areas of clinical medicine — and for good reason. After 40, most men are dealing with a measurable, progressive decline in growth hormone, testosterone, and other signalling molecules that govern body composition, energy, sleep, and cognitive performance. This is not a lifestyle problem. It is a biological one.

This guide explains what peptide therapy is, which peptides have the strongest evidence for men in andropause, how a clinician-guided protocol is structured, and what you should expect in terms of outcomes. No hype. No speculation. Just what the science and clinical practice actually show.

What Happens to Male Hormones After 40

After 40, the hormonal environment in the male body shifts in ways that compound each other.

Testosterone declines at roughly 1–2% per year from age 30 onward. By 45, many men have total testosterone levels in the low-normal range — technically "within range" but meaningfully lower than they were a decade before. Free testosterone — the biologically active fraction — drops faster because sex hormone-binding globulin (SHBG) tends to increase with age, binding more testosterone and reducing what is available to tissue.

Growth hormone (GH) follows a steeper trajectory. GH secretion declines by approximately 14% per decade after age 25, according to data from the New England Journal of Medicine. Since GH is responsible for stimulating IGF-1 — which drives protein synthesis, fat metabolism, and cellular repair — its decline has metabolic consequences that accumulate quietly over years.

Insulin sensitivity worsens in parallel. Visceral fat accumulates. Inflammatory markers rise. Muscle mass falls. The clinical picture that emerges — often dismissed as "normal ageing" — is what medicine now recognises as andropause: a genuine hormonal transition with measurable biochemical drivers and evidence-based interventions.

The symptoms men most commonly report include:

• Persistent fatigue despite adequate sleep
• Loss of lean muscle mass and increasing abdominal fat
• Brain fog and reduced motivation
• Poor sleep quality, particularly disrupted deep-sleep stages
• Reduced libido and lower exercise tolerance
• Irritability and mood instability

These are not personality changes. They are downstream effects of hormonal insufficiency. And they are addressable.

What Are Peptides, and Why Are They Relevant to Men Over 40?

Peptides are short chains of amino acids — smaller than proteins — that act as signalling molecules in the body. They do not introduce exogenous hormones. Instead, they work upstream: stimulating your own glands to produce hormones in a more physiological, pulsatile pattern.

This is clinically significant. Exogenous testosterone, for example, can suppress the hypothalamic-pituitary-gonadal (HPG) axis and impair natural production over time. Many peptides work differently — they prompt the body's own regulatory systems to function closer to how they did in youth.

For men over 40 dealing with andropause and metabolic decline, the most clinically relevant peptide classes are:

1. Growth hormone secretagogues (GHSs) — stimulate the pituitary to release GH
2. Growth hormone-releasing hormone (GHRH) analogues — mimic the hypothalamic signal that drives GH pulses
3. Repair and regenerative peptides — support tissue healing and reduce systemic inflammation

Each class targets a different part of the hormonal cascade. A well-designed men 40 peptide protocol will often combine two or more peptides to produce synergistic effects.

Peptides for Men Over 40 Hormonal Health: The Evidence-Based Options

CJC-1295 and Ipamorelin: The Foundational GH Stack

CJC-1295 is a GHRH analogue. Ipamorelin is a selective GH secretagogue. Used together, they produce a strong, physiological GH pulse without meaningfully raising cortisol or prolactin — two common side effects of less selective secretagogues like GHRP-6.

A clinical study published in the Journal of Clinical Endocrinology & Metabolism demonstrated that CJC-1295 produced sustained, dose-dependent increases in GH and IGF-1 levels over weeks, with a favourable safety profile. The combination with ipamorelin amplifies GH pulse amplitude by acting on different receptors simultaneously.

What men report clinically:

• Improved deep sleep within 2–4 weeks (GH is predominantly secreted during slow-wave sleep)
• Gradual lean mass gain and reduction in visceral adiposity over 3–6 months
• Improved energy and recovery from exercise
• Better skin quality and joint comfort

Typical protocol: 200–300 mcg of each peptide subcutaneously, 5 nights per week, injected 30–60 minutes before sleep on an empty stomach. Duration: 3–6 months minimum for meaningful body composition changes.

Sermorelin: The Gentler Entry Point

Sermorelin is a truncated fragment of endogenous GHRH — the first 29 amino acids. It has a shorter half-life than CJC-1295 and produces a more modest, though still clinically meaningful, increase in GH output.

Its shorter half-life is actually an advantage for certain patients: it mirrors the natural pulsatile pattern of GH release more closely and has a lower likelihood of GH-receptor downregulation with extended use.

Adult clinical programs with sermorelin have shown consistent reductions in visceral and subcutaneous fat, modest gains in lean muscle, and better sleep architecture over 6–12 months of nightly therapy. Average fat-mass reduction in clinical case series sits at 5–7% over this period.

Sermorelin is often the preferred starting point for men who are new to peptide therapy, those with more conservative clinical profiles, or those whose clinicians prefer a gentler GH stimulus while monitoring IGF-1 response before progressing to a more potent protocol.

Tesamorelin: Targeted Visceral Fat Reduction

Tesamorelin is an FDA-approved GHRH analogue — the only one with regulatory approval for a specific metabolic indication: reduction of excess visceral adipose tissue in HIV-associated lipodystrophy. This regulatory history matters. It means tesamorelin has undergone controlled clinical trials that most compounded peptides have not.

Pivotal trials showed tesamorelin produced a 15–18% reduction in visceral fat compared to placebo over 26 weeks, alongside increases in IGF-1, improvements in lipid profiles, and reduction in C-reactive protein — an inflammation marker closely associated with cardiovascular risk.

For men over 40 with significant visceral adiposity, insulin resistance, or metabolic syndrome, tesamorelin offers the most targeted mechanism of the GH secretagogue class. It is typically prescribed at 1–2 mg subcutaneously daily.

Its clinical relevance for andropause peptide therapy lies in its dual metabolic action: it does not simply improve body composition cosmetically — it reduces the visceral fat depot that directly drives insulin resistance, dyslipidaemia, and cardiometabolic risk in middle-aged men.

BPC-157: Systemic Repair and Inflammation Reduction

BPC-157 (Body Protective Compound 157) is a synthetic pentadecapeptide derived from a protein found in gastric juice. It does not act on the GH axis. Instead, it operates through several parallel pathways: upregulating growth hormone receptor expression in tendons and ligaments, modulating nitric oxide signalling, and reducing systemic inflammatory cytokines.

Preclinical data, primarily from rodent models, shows BPC-157 accelerates healing of muscle, tendon, ligament, and bone injuries — at a rate that consistently outperforms controls in peer-reviewed studies. A 2018 review in Current Pharmaceutical Design summarised the breadth of tissue-protective effects, including cytoprotective properties in gut lining and vascular endothelium.

For men over 40, BPC-157 is most clinically relevant for:

• Recovery from musculoskeletal injuries and overuse conditions
• Gut integrity support (particularly relevant for men with inflammatory gut conditions)
• Reducing systemic inflammation, which compounds hormonal insufficiency
• Adjunct support during heavy training or strength conditioning phases

It is not a GH secretagogue. Its value is in restoration and recovery — reducing the inflammatory burden that blunts hormonal signalling and impairs training adaptations. It is frequently used alongside CJC-1295/ipamorelin as part of a broader men 40 peptide protocol.

PT-141 (Bremelanotide): Libido and Sexual Function

PT-141 acts on melanocortin receptors in the central nervous system — particularly MC3R and MC4R — to increase sexual desire and arousal. Unlike PDE5 inhibitors (sildenafil, tadalafil), which work peripherally on vascular smooth muscle, PT-141 works centrally through the CNS.

This distinction matters clinically: PT-141 addresses the neurological component of sexual dysfunction, which is frequently the dominant mechanism in men with andropause-related libido decline. Low testosterone dampens desire at the receptor level. PT-141 can bypass that deficit by activating the arousal pathway directly.

Phase II and Phase III clinical trials demonstrated statistically significant improvements in sexual desire and erectile function in men with erectile dysfunction, including those who had failed to respond to PDE5 inhibitors. PT-141 is FDA-approved under the brand name Vyleesi (for women), and is used off-label in men under clinician guidance.

Typical dosing: 1–2 mg subcutaneously, taken 45–90 minutes before anticipated sexual activity, as needed.

Peptides for Men Over 40 Hormonal Health: Choosing the Right Protocol

This is where self-directed peptide use most commonly fails — and where clinician guidance is not optional. Peptide choice should be driven by your specific hormonal and metabolic presentation, not by what is trending in men's health forums.

A competent evaluation should include:

Without this baseline, you are guessing. With it, your clinician can match the right peptide — or combination — to your specific deficit profile, set a realistic outcome timeline, and monitor for both response and safety.

How a Clinician-Structured Andropause Peptide Protocol Looks in Practice

Here is what a phased approach typically looks like for a man aged 45–60 presenting with low-normal testosterone, elevated visceral fat, poor sleep, and low IGF-1:

Phase 1 — Months 1–3: Foundation and Sleep Restoration

1. Begin sermorelin or CJC-1295/ipamorelin at therapeutic dose, 5 nights per week before sleep
2. Recheck IGF-1 at 6–8 weeks — target is upper quarter of age-appropriate range, not supraphysiological
3. Track subjective sleep quality, energy, and morning recovery

Phase 2 — Months 3–6: Body Composition and Metabolic Optimisation

1. If visceral fat and insulin resistance are primary concerns, consider transitioning or adding tesamorelin
2. Introduce BPC-157 if musculoskeletal recovery is a concurrent goal
3. Recheck fasting insulin, lipids, and CRP to assess metabolic response

Phase 3 — Months 6+: Maintenance or Protocol Refinement

1. Reassess full panel
2. Adjust peptide selection and dosing based on response data
3. Determine whether continued therapy or a structured protocol break is appropriate — "on" and "off" cycling is standard practice to preserve receptor sensitivity

PT-141 is used as needed throughout any phase, independent of the core protocol.

What to Expect: Realistic Timelines

Men new to peptide therapy commonly overestimate short-term results and underestimate long-term gains. Here is what the evidence and clinical practice actually support:

These are population-level averages. Individual variation depends on baseline hormonal status, training consistency, nutrition, sleep hygiene, and the quality of clinical oversight guiding the protocol.

What Men Over 40 Should Not Do With Peptide Therapy

Being clear about this is important:

• Do not self-prescribe. Without baseline labs, you cannot know which peptide is appropriate, what dose is safe, or whether you are responding. IGF-1 levels that go supraphysiological carry insulin resistance and potential oncological risks.
• Do not use unverified compounding sources. Peptide quality varies dramatically. Contaminated or mislabelled compounds are a documented problem. Use pharmacy-compounded peptides prescribed by a licensed clinician.
• Do not expect peptides to compensate for poor fundamentals. Sleep deprivation, chronic caloric surplus, sedentary behaviour, and unmanaged stress blunt every hormonal intervention. Peptides work synergistically with a disciplined lifestyle — they do not override one.
• Do not skip follow-up labs. The risk of GH secretagogues is not acute — it is longitudinal. Insulin sensitivity should be monitored every 3–6 months. IGF-1 should be checked 6–8 weeks after initiation.

The Role of Integrated Metabolic Care in Male Hormonal Restoration

Peptide therapy does not exist in isolation. For men over 40 with andropause symptoms, a comprehensive approach addresses the entire metabolic picture.

That means evaluating insulin resistance, dyslipidaemia, and metabolic syndrome as interconnected with hormonal decline — not as separate conditions. Visceral fat impairs testosterone signalling. Insulin resistance blunts GH response. Elevated inflammation suppresses pituitary function. These pathways reinforce each other in both directions.

Effective male metabolic health peptides work best when the clinician treating you understands this interconnection — and has the tools to evaluate and treat the whole picture. Meto's approach to andropause is built on exactly this: board-certified specialist evaluation, personalised laboratory assessment, and ongoing monitoring rather than protocol-based prescription.

Conclusion

Peptide therapy is not a shortcut. It is a precision tool — and like all precision tools, it requires the right assessment before use.

For men over 40 navigating andropause, declining GH output, and the metabolic consequences that follow, a well-structured protocol — anchored in lab data, supervised by a specialist, and monitored over time — can produce meaningful, durable improvements in body composition, energy, sleep, cognitive clarity, and metabolic health.

The biology is clear. What you need is a clinician who understands it and a care structure built around your specific profile.

Book a men's hormonal and metabolic consult with a Meto specialist today.

Frequently Asked Questions

What is the best peptide for men over 40 to start with?

There is no single "best" peptide independent of an individual's lab results. For most men with low IGF-1, poor sleep, and early body composition changes, CJC-1295 combined with ipamorelin is a strong foundational protocol. Men with primarily visceral fat concerns and insulin resistance may benefit more from tesamorelin. A baseline lab panel is necessary before selecting any peptide.

Are peptides safe for men with elevated PSA or prostate concerns?

This is a clinical question that must be answered by a physician reviewing your full history, current PSA trend, and urological status. Peptides that work through the GH axis do not directly stimulate androgen receptors the way testosterone does, but any intervention affecting body composition and metabolic state warrants baseline and ongoing PSA monitoring. Do not begin peptide therapy without disclosing prostate history to your prescribing clinician.

How long does andropause peptide therapy typically last?

Most protocols are run for 3–6 month cycles, followed by reassessment. Some men continue on maintenance protocols indefinitely with clinical oversight; others achieve sustained improvements and cycle off. Duration is determined by your hormonal response, IGF-1 trajectory, metabolic markers, and clinical goals — not by a fixed timeline.

Will peptides raise my testosterone levels?

GH secretagogues do not directly raise testosterone. However, because GH and testosterone interact through shared metabolic pathways — and because improvements in body composition, sleep, and inflammation indirectly support testosterone signalling — some men do see modest improvements in testosterone alongside GH axis optimisation. If testosterone deficiency is clinically significant, testosterone replacement therapy (TRT) may be indicated alongside peptide therapy, under specialist supervision.

Can I combine peptides with other hormonal therapies like TRT?

Yes, in many cases peptides and TRT are used together under clinician guidance. They work through different mechanisms — TRT addresses the androgen axis directly; GH secretagogues address the somatotropic axis. A comprehensive andropause treatment plan may incorporate both, depending on your baseline hormonal profile.

How do I know if I need a peptide protocol or just lifestyle changes?

Lab work answers this question definitively. If your IGF-1 is in the lower quartile for your age group, your free testosterone is suppressed, and your visceral fat and inflammatory markers are elevated, lifestyle modifications alone are unlikely to restore hormonal function to a meaningful degree. Peptide therapy becomes clinically relevant when the hormonal decline is beyond what behaviour change alone can address.